Literature DB >> 28385379

Specific gene expression profiles are associated with a pathologic complete response to neoadjuvant therapy in esophageal adenocarcinoma.

Patrick J McLaren1, Anthony P Barnes2, Willy Z Terrell1, Gina M Vaccaro3, Jack Wiedrick4, John G Hunter1, James P Dolan5.   

Abstract

BACKGROUND: Predicting treatment response to chemo-radiotherapy (CRT) in esophageal cancer remains an unrealized goal despite studies linking constellations of genes to prognosis. We aimed to determine if specific expression profiles are associated with pathologic complete response (pCR) after neoadjuvant CRT.
METHODS: Eleven genes previously associated with esophageal cancer prognosis were identified. Esophageal adenocarcinoma (EAC) patients treated with neoadjuvant CRT and esophagectomy were included. Patients were classified into two groups: pCR and no-or-incomplete response (NR). Polymerase chain reaction was used to evaluate gene expression. Omnibus testing was applied to overall gene expression differences between groups, and log-rank tests compared individual genes.
RESULTS: Eleven pCR and eighteen NR patients were analyzed. Combined expression profiles were significantly different between pCR and NR groups (p < 0.01). The gene CCL28 was over-expressed in pCR patients (Log-HR: 1.53, 95%CI: 0.46-2.59, p = 0.005), and DKK3 was under-expressed in pCR (Log-HR: -1.03 95%CI: -1.97, -0.10, p = 0.031).
CONCLUSION: EAC tumors that demonstrated a pCR have genetic profiles that are significantly different from typical NR profiles. The genes CCL28 and DKK3 are potential predictors of treatment response.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; Esophageal cancer; Gene expression; Neoadjuvant therapy; Pathologic complete response

Mesh:

Substances:

Year:  2017        PMID: 28385379      PMCID: PMC6367123          DOI: 10.1016/j.amjsurg.2017.03.024

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  29 in total

1.  Transthoracic versus transhiatal esophagectomy: a prospective study of 945 patients.

Authors:  Jeffrey Rentz; David Bull; David Harpole; Stephen Bailey; Leigh Neumayer; Theodore Pappas; Barbara Krasnicka; William Henderson; Jennifer Daley; Shukri Khuri
Journal:  J Thorac Cardiovasc Surg       Date:  2003-05       Impact factor: 5.209

2.  Outcomes after esophagectomy: a ten-year prospective cohort.

Authors:  Stephen H Bailey; David A Bull; David H Harpole; Jeffrey J Rentz; Leigh A Neumayer; Theodore N Pappas; Jennifer Daley; William G Henderson; Barbara Krasnicka; Shukri F Khuri
Journal:  Ann Thorac Surg       Date:  2003-01       Impact factor: 4.330

3.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Authors:  Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-23       Impact factor: 44.544

4.  Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation.

Authors:  Rajyalakshmi Luthra; Tsung-Teh Wu; Madan G Luthra; Julie Izzo; Enrique Lopez-Alvarez; Li Zhang; Jaime Bailey; Jeffrey H Lee; Robert Bresalier; Asif Rashid; Stephen G Swisher; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2005-12-12       Impact factor: 44.544

5.  A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia.

Authors:  Christopher J Peters; Jonathan R E Rees; Richard H Hardwick; James S Hardwick; Sarah L Vowler; Chin-Ann J Ong; Chunsheng Zhang; Vicki Save; Maria O'Donovan; Doris Rassl; Derek Alderson; Carlos Caldas; Rebecca C Fitzgerald
Journal:  Gastroenterology       Date:  2010-06-02       Impact factor: 22.682

Review 6.  Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival.

Authors:  Adam C Berger; Jeffrey Farma; Walter J Scott; Gary Freedman; Louis Weiner; Jonathan D Cheng; Hao Wang; Melvyn Goldberg
Journal:  J Clin Oncol       Date:  2005-03-21       Impact factor: 44.544

Review 7.  Pro-metastasis function of TGFbeta mediated by the Smad pathway.

Authors:  Yibin Kang
Journal:  J Cell Biochem       Date:  2006-08-15       Impact factor: 4.429

Review 8.  TGF-beta signaling in tumor suppression and cancer progression.

Authors:  R Derynck; R J Akhurst; A Balmain
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

9.  Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study.

Authors:  Peter McCulloch; Jeremy Ward; Paris P Tekkis
Journal:  BMJ       Date:  2003-11-22

10.  Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer.

Authors:  Stephen G Maher; Charles M Gillham; Shane P Duggan; Paul C Smyth; Nicola Miller; Cian Muldoon; Kenneth J O'Byrne; Orla M Sheils; Donal Hollywood; John V Reynolds
Journal:  Ann Surg       Date:  2009-11       Impact factor: 12.969

View more
  3 in total

Review 1.  Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer.

Authors:  Anita Lavery; Richard C Turkington
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-01-08

Review 2.  Predicting Response to Neoadjuvant Therapy in Oesophageal Adenocarcinoma.

Authors:  William Jiang; Jelske M de Jong; Richard van Hillegersberg; Matthew Read
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

3.  Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: a preliminary study based on the screening of serum markers using protein chips.

Authors:  Qiang Tong; Xiao-Long Wang; Sheng-Bao Li; Gong-Li Yang; Shu Jin; Zi-Ye Gao; Xiao-Bo Liu
Journal:  Onco Targets Ther       Date:  2018-09-12       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.